Allena Pharmaceuticals, Inc. (ALNA)

Sorry, no known transcripts

Recent filings

Allena Pharmaceuticals, Inc.'s President and CEO just picked up 85,254 shares - Nov. 17, 2021

Quarterly report [Sections 13 or 15(d)] - Nov. 12, 2021

Quarterly report [Sections 13 or 15(d)] - Nov. 12, 2021

Allena Pharmaceuticals, Inc. Just Filed Its Quarterly Report: 3. Net Loss per Shar... - Nov. 12, 2021

Annual report [Section 13 and 15(d), not S-K Item 405] - Nov. 12, 2021

Allena Pharmaceuticals Reports Third Quarter 2021 Financial Results And Recent Corporate Progress - Nov. 10, 2021

Allena Pharmaceuticals Commences Dosing Of Gout Patients In Second Phase 2A Trial Of ALLN-346 - Sept. 29, 2021

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or - Aug. 27, 2021

Allena Pharmaceuticals, Inc. Just Filed Its Quarterly Report: 3. Net Loss per Shar... - Aug. 12, 2021

Allena Pharmaceuticals: Results Of Operations And Financial Condition - Aug. 10, 2021

Allena Pharmaceuticals Announces $28 Million Registered Direct Offering Priced - July 16, 2021

Allena Pharmaceuticals, Inc. just filed a prospectus, suggesting it plans to soon issue some securities - July 15, 2021

Allena Pharmaceuticals Provides Update On Clinical Development Programs - July 13, 2021

Allena Pharmaceuticals, Inc. director was just granted 37,000 options - June 4, 2021

Allena Pharmaceuticals, Inc. director was just granted 37,000 options - June 4, 2021

Allena Pharmaceuticals, Inc. director was just granted 37,000 options - June 4, 2021

Allena Pharmaceuticals, Inc. director was just granted 37,000 options - June 4, 2021

Statement of changes in beneficial ownership of securities - June 4, 2021

Current report, items 5.03, 5.07, 8.01, and 9.01 - June 4, 2021

Additional definitive proxy soliciting materials and Rule 14(a)(12) material - May 20, 2021

Allena Pharmaceuticals, Inc. Just Filed Its Quarterly Report: 3. Net Loss per Shar... - May 13, 2021

Notice of Effectiveness - May 12, 2021

Statement of changes in beneficial ownership of securities - May 12, 2021

Current report, items 2.02 and 9.01 - May 11, 2021

Registration statement under Securities Act of 1933 - May 6, 2021

Allena Pharmaceuticals: Form, Schedule Or Registration Statement No - May 6, 2021

Other definitive proxy statements - April 22, 2021

Allena Pharmaceuticals: Form, Schedule Or Registration Statement No - April 22, 2021

Other preliminary proxy statements - April 12, 2021

Initial statement of beneficial ownership of securities - April 8, 2021

Allena Pharmaceuticals, Inc. director was just granted 74,000 options - April 8, 2021

Allena Pharmaceuticals Appoints Mark J. Fitzpatrick To Its Board Of Directors - April 7, 2021

Financial Statements and - April 2, 2021

Entry Into a Material Definitive - March 30, 2021

Allena Pharmaceuticals, Inc. just filed a prospectus, suggesting it plans to soon issue some securities - March 30, 2021

Securities to be offered to employees in employee benefit plans - March 11, 2021

Securities to be offered to employees in employee benefit plans - March 11, 2021

Annual report [Section 13 and 15(d), not S-K Item 405] - March 11, 2021

Allena Pharmaceuticals: Results Of Operations And Financial Condition - March 9, 2021

Shareholder Director Nominations - March 5, 2021

Allena Pharmaceuticals, Inc.'s President and COO was just granted 886,400 options - Feb. 17, 2021

BVP VII Special Opportunity Fund L.P. just issued a filing suggesting it has sold all of its Allena Pharmaceuticals, Inc. - Feb. 16, 2021

Statement of acquisition of beneficial ownership by individuals - Feb. 8, 2021

Allena Pharmaceuticals, Inc.'s Chief Financial Officer just declared ownership of no shares of Allena Pharmaceuticals, Inc. - Feb. 2, 2021

Allena Pharmaceuticals, Inc.'s Chief Financial Officer was just granted 400,000 options - Feb. 2, 2021

Allena Pharmaceuticals Appoints Richard D. Katz, M.D. As Chief Financial Officer - Feb. 2, 2021

Departure of Directors or Certain - Jan. 28, 2021

Statement of acquisition of beneficial ownership by individuals - Jan. 25, 2021

Martin D. Hoe just issued a filing suggesting it has sold all of its Allena Pharmaceuticals, Inc. - Jan. 13, 2021

Sabby Volatility Warrant Master Fund, Ltd. just provided an update on share ownership of Allena Pharmaceuticals, Inc. - Jan. 6, 2021

Allena Pharmaceuticals, Inc.'s President and CEO just picked up 144,816 shares - Dec. 18, 2020

Allena Pharmaceuticals, Inc.'s Chief Financial Officer just picked up 96,272 shares - Dec. 18, 2020

Allena Pharmaceuticals, Inc.'s President and COO was just granted 209,303 restricted shares - Dec. 10, 2020

Steven A. Cohen just provided an update on share ownership of Allena Pharmaceuticals, Inc. - Dec. 10, 2020

Notice of Effectiveness - Dec. 4, 2020

Sorry, no schedule available for this company

Allena Pharmaceuticals to Participate in the Stifel 2021 Virtual Healthcare Conference - Nov. 15, 2021

Allena Pharmaceuticals Reports Third Quarter 2021 Financial Results and Recent Corporate Progress - Nov. 10, 2021

Allena Pharmaceuticals Receives Fast Track Designation from FDA for the Development of ALLN-346 for Chronic Treatment of Hyperuricemia in Patients With Gout and Advanced Chronic Kidney Disease - Nov. 3, 2021

Allena Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Corporate Progress - Aug. 10, 2021

Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Aug. 3, 2021

Allena Pharmaceuticals to Participate in the 12th Annual Wedbush PacGrow Healthcare Conference - Aug. 3, 2021

Allena Pharmaceuticals Announces $28 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules - July 13, 2021

Allena Pharmaceuticals, Inc. to Present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference - July 8, 2021

Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - July 7, 2021

Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - June 8, 2021

Allena Pharmaceuticals to Host Key Opinion Leader Webinar Focused on ALLN-346 for the Treatment of Gout in Patients with Chronic Kidney Disease - June 8, 2021

Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - April 8, 2021

Allena Pharmaceuticals Appoints Mark J. Fitzpatrick to its Board of Directors - April 7, 2021

Allena Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update - March 9, 2021

Allena Pharmaceuticals to Present at Upcoming Investor Conferences in March - Feb. 24, 2021

Allena Pharmaceuticals Appoints Richard D. Katz, M.D. as Chief Financial Officer - Feb. 2, 2021

Allena Pharmaceuticals to Present at Upcoming Investor Conferences in January - Jan. 4, 2021

Allena Pharmaceuticals Announces Appointment of David J. Clark, M.D., M.R.C.P. as Chief Medical Officer - Dec. 1, 2020

Allena Pharmaceuticals Announces $10.0 Million Bought Deal Offering - Dec. 1, 2020

Allena Pharmaceuticals Increases Previously Announced Bought Deal to $13.0 Million - Dec. 1, 2020

 


Feedback